Fractyl Health, Inc. Common Stock (GUTS) - Net Assets
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has net assets worth $-3.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.27 Million) and total liabilities ($117.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Fractyl Health, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.18 Million |
| % of Total Assets | -2.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | 90.11% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Fractyl Health, Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Fractyl Health, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Fractyl Health, Inc. Common Stock balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Fractyl Health, Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Fractyl Health, Inc. Common Stock from 2019 to 2024. For live valuation and market cap data, see Fractyl Health, Inc. Common Stock (GUTS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $28.42 Million | +108.74% |
| 2023-09-30 | $-325.06 Million | -28.83% |
| 2022-09-30 | $-252.32 Million | -20.54% |
| 2021-09-30 | $-209.32 Million | -1500.07% |
| 2020-09-30 | $14.95 Million | +110.38% |
| 2019-09-30 | $-144.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fractyl Health, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26145300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $443.73 Million | 1561.12% |
| Total Equity | $28.42 Million | 100.00% |
Fractyl Health, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aeternal Mentis SA
MC:AMEN
|
$107.28 Million |
|
BRIG.M3 EUROP.ACQ.A-0001
F:KN2
|
$107.30 Million |
|
Uniquest
KO:077500
|
$107.30 Million |
|
Donegal Group B Inc
NASDAQ:DGICB
|
$107.30 Million |
|
Moda-InnoChips Co. Ltd
KQ:080420
|
$107.23 Million |
|
N. Varveris-Moda Bagno S.A
AT:MODA
|
$107.22 Million |
|
RoboRobo Co. Ltd
KQ:215100
|
$107.21 Million |
|
Korea Cast Pip
KO:000970
|
$107.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fractyl Health, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -325,062,000 to 28,424,000, a change of 353,486,000.
- Net loss of 68,694,000 reduced equity.
- New share issuances of 103,695,000 increased equity.
- Other factors increased equity by 318,485,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.69 Million | -241.68% |
| Share Issuances | $103.69 Million | +364.81% |
| Other Changes | $318.49 Million | +1120.48% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Fractyl Health, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $-3.02 | $0.70 | x |
| 2020-09-30 | $0.31 | $0.70 | x |
| 2021-09-30 | $-4.40 | $0.70 | x |
| 2022-09-30 | $-5.30 | $0.70 | x |
| 2023-09-30 | $-6.83 | $0.70 | x |
| 2024-09-30 | $0.65 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fractyl Health, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -241.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -73864.52%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.80x
- Recent ROE (-241.68%) is below the historical average (-74.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.19 Million |
| 2020 | -203.87% | 0.00% | 0.00x | 2.32x | $-31.98 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.80 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.22 Million |
| 2023 | 0.00% | -64242.50% | 0.00x | 0.00x | $-44.58 Million |
| 2024 | -241.68% | -73864.52% | 0.00x | 3.80x | $-71.54 Million |
Industry Comparison
This section compares Fractyl Health, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fractyl Health, Inc. Common Stock (GUTS) | $-3.18 Million | 0.00% | N/A | $107.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel ade… Read more